Goldman Sachs Names 2 Undervalued Healthcare Stocks to Buy With At Least 50% Upside
Healthcare has long appealed to investors for its growth potential. Within the sector, biotech sits at the riskier end of the spectrum, but it can ...
Insmed Inc (INSM)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 8,796,111 | $937,841,355 | +19% | 4.7% |
| 2. | Darwin Global Management Abhishek Trehan | 6,431,163 | $673,600,013 | -62% | 17.91% |
| 3. | Orbis Investment Management William B. Gray | 6,076,487 | $647,875,044 | +225% | 2.23% |
| 4. | D E Shaw D. E. Shaw | 5,877,959 | $626,707,989 | +5% | 0.3% |
| 5. | Citadel Investment Group Ken Griffin | 2,556,973 | $272,624,461 | +18% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $66.35 | 1,130 | $74,975.50 | 3,025 | 2025-05-21 | Filing | |
| $66.87 | 1,895 | $126,718.65 | 1,895 | 2025-05-20 | Filing | |
| $19.29 | 10,000 | $192,900.00 | 10,000 | 2023-05-15 | Filing | |
| $19.29 | 10,000 | $192,900.00 | 298,615 | 2023-05-15 | Filing | |
| $17.70 | 10,000 | $177,000.00 | 15,900 | 2022-11-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $124.00 | 25,000 | $3,100,000.00 | 39,238 | 2026-09-09 | Filing | |
| $127.53 | 5,000 | $637,650.00 | 0 | 2026-08-17 | Filing | |
| $133.27 | 239,850 | $31,964,809.50 | 98,744 | 2026-08-10 | Filing | |
| $129.40 | 18,278 | $2,365,173.20 | 60,486 | 2026-08-06 | Filing | |
| $127.00 | 8,895 | $1,129,665.00 | 78,764 | 2026-08-06 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 648 | $73,963 | 0.01% | |
| 2. | 15 | $1,712 | 0% | |
| 3. | 9 | $1,027 | 0% | |
| 4. | 404 | $46 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
Insmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients?
Insmed Incorporated (NASDAQ:INSM) announced on September 21 that the FDA accepted its supplemental application for ARIKAYCE and granted priority review, setting January 28, 2027, as the target decision...
The Fund Exited Insmed (INSM) After the Investment Thesis Played Out
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second-quarter 2026 investor letter. The letter can be downloaded here.
Exiting Insmed (INSM) Following Disappointing Key Drug Uptake
American Century Investments, an investment management company, released its second-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”.
Do You Believe in Insmed's INSM) Long-Term Potential Despite Short-Term Challenges?
Artisan Partners, an investment management company, released its second-quarter 2026 investor commentary for the "Artisan Global Opportunities Strategy". The letter can be downloaded here.
Insmed's (INSM) New Drug Launch Is Reshaping The Whole Business
On August 6, Insmed (NASDAQ:INSM) reported second-quarter results that mark a turning point for a company long defined by red ink.
Insmed (INSM) Soars 33.86% as Brinsupri Drives Fourfold Growth. Here's What to Watch Next
Insmed (NASDAQ:INSM) saw its share price increase by 33.86 percent on Thursday to close at $132.55 apiece after nearly quadrupling its revenues in the second quarter of the year, thanks to a strong uptake...
Here's Why Baron Health Care Fund Remains Bullish on Insmed (INSM)
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here.
Insmed Incorporated's (INSM) Commercial Acceleration Overshadows Q1 Stumble
Carillon Tower Advisers, an investment management company, released its second-quarter 2026 investor letter for the “Carillon Eagle Mid Cap Growth Fund”.
Concerns Over the Pace of its Brinsupri’s Launch Hurt Insmed (INSM)
ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “Small Cap Growth Strategy”. A copy of the letter can be downloaded here.
Hedge Fund Resource Center